Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide

First Posted Date: 2014-06-24

Last Posted Date: 2014-10-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 78

Registration Number: NCT02172313

A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin detemir
Drug: human soluble insulin

First Posted Date: 2014-06-12

Last Posted Date: 2014-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT02162407

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-06-11

Last Posted Date: 2014-12-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT02161588

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Inflammation
Rheumatoid Arthritis
Healthy

Interventions: Drug: placebo
Drug: NNC 0151-0000-0000

First Posted Date: 2014-05-30

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT02151409

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Type 2 Diabetes Mellitus

Interventions: Drug: insulin degludec
Drug: Insulin icodec
Drug: placebo

First Posted Date: 2014-05-28

Last Posted Date: 2021-03-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 49

Registration Number: NCT02148861

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-05-26

Last Posted Date: 2018-08-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 38

Registration Number: NCT02147431

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-05-23

Last Posted Date: 2018-04-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT02146079

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

Phase 3

Completed

Conditions: Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: nonacog beta pegol

First Posted Date: 2014-05-19

Last Posted Date: 2024-03-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 54

Registration Number: NCT02141074

Locations: 🇺🇸
Univ of Utah Primary Children's Hospital, Salt Lake City, Utah, United States
🇦🇹
Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie, Graz, Austria
🇬🇧
Birmingham Children's Hospital, Birmingham, United Kingdom

and more 42 locations

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2014-05-14

Last Posted Date: 2024-10-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 124

Registration Number: NCT02137850

Locations: 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
Arizona H&T Phoenix Child Hosp, Phoenix, Arizona, United States
🇺🇸
Rush University Med. Cntr, Chicago, Illinois, United States

and more 50 locations

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Phase 3

Terminated

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin NPH
Drug: Insulin detemir
Behavioral: Diet/exercise

First Posted Date: 2014-05-06

Last Posted Date: 2018-09-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT02131272

Locations: 🇹🇷
Novo Nordisk Investigational Site, Kayseri, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy